3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms
6
Leukemia
5
Neoplasms by Histologic Type
4
Myeloproliferative Disorders
4
Leukemia, Myeloid
4
Hematologic Diseases
4
Carcinoma, Non-Small-Cell Lung
4
Bone Marrow Diseases
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoproliferative Disorders
2
Lymphatic Diseases
2
Leukemia, Myeloid, Chronic-Phase
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Thyroid Neoplasms
1
Small Cell Lung Carcinoma
1
Piebaldism
1
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Malignant Hepatobiliary Neoplasm
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Adenocarcinoma of Lung
1
Interventions
fludarabine phosphate
31
Peripheral Blood Stem Cell Transplantation
26
Cyclophosphamide
25
Mycophenolic Acid
24
Whole-Body Irradiation
23
Busulfan
21
Tacrolimus
19
Cyclosporine
19
Antilymphocyte Serum
14
Methotrexate
13
Imatinib Mesylate
12
Cord Blood Stem Cell Transplantation
11
Melphalan
10
Dasatinib
10
Cyclosporins
8
nilotinib
7
Methylprednisolone
7
Etoposide
7
Radiotherapy
6
Filgrastim
6
Alemtuzumab
6
Sirolimus
5
thymoglobulin
4
sargramostim
4
bosutinib
4
Granulocyte Colony-Stimulating Factor
4
Cytarabine
4
fludarabine
3
Thiotepa
3
Rituximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Leukemia, Myeloid, Chronic-Phase
×
ponatinib
×
Clear all
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts